Cel Sci (CVM) Convertible Debt (2011)

Cel Sci (CVM) posted Convertible Debt of $3.0 million for Q4 2011, down 40.89% sequentially from $5.0 million in Q3 2011.

Cel Sci (CVM) Convertible Debt (2011) Analysis & Trends

Cel Sci has reported Convertible Debt for 1 years, with the latest figure at $3.0 million in Q4 2011.

Quarterly Convertible Debt changed N/A year-over-year to $3.0 million in Q4 2011, while the trailing twelve-month figure through Dec 2011 was $3.0 million (changed N/A YoY) and the FY2011 annual result came in at $5.0 million, changed N/A from the prior year.
Convertible Debt slipped to $3.0 million in Q4 2011 per CVM's latest filing, from $5.0 million in the prior quarter.
Over five years, Convertible Debt peaked at $5.0 million in Q3 2011 and troughed at $3.0 million in Q4 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cel Sci	2.12 Mn	-4.42 Mn	-

Download Data